11 completed, 2 recruiting, 1 terminated, 1 unknown. 15 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 11, Recruiting 2, Terminated 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Fluvoxamine: new trials by email Literature Review of Fluvoxamine trials Research Report on Fluvoxamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19 Fluvoxamine, Placebo - Post-COVID, POST-Covid 19 | Phase 3 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 160 | 2026-06-04 | 2026-06-09 |
| Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery Fluvoxamine, Placebo - Delirium, Surgery-Complications | Phase 3 | Recruiting | Washington University School of Medicine | 46 | 2026-04-06 | 2026-04-29 |
| A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial Fluvoxamine Maleate 100 MG, Placebo, Metformin Extended Release Oral Tablet - Long COVID-19 Syndrome, Chronic Fatigue Syndrome | Phase 3 | Completed | Cardresearch | 399 | 2023-10-18 | 2026-04-13 |
| Fluvoxamine for Long COVID-19 Fluvoxamine - Long COVID | Phase 2 / Phase 3 | Completed | Washington University School of Medicine | 191 | 2023-05-15 | 2026-10-07 |
| ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100) Fluvoxamine, Placebo - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 1208 | 2022-08-25 | 2024-11-15 |
| ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine) Fluvoxamine, Placebo - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 1331 | 2021-06-08 | 2023-09-26 |
| ACTIV-6: COVID-19 Study of Repurposed Medications Ivermectin, Fluvoxamine, Fluticasone - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 10956 | 2021-06-08 | 2025-11-17 |
| Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms Spirulin Platensis, Budesonide Powder, Fluoxetine 20 MG - Covid19, SARS-Associated Coronavirus | Phase 3 | Unknown | Cardresearch | 7819 | 2021-01-19 | 2024-05-08 |
| COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) Metformin, Placebo, Fluvoxamine - Covid19, SARS-CoV Infection | Phase 3 | Completed | University of Minnesota | 1323 | 2021-01-01 | 2026-04-24 |
| Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2) Fluvoxamine, Placebo - Covid19, Coronavirus | Phase 3 | Completed | Washington University School of Medicine | 670 | 2020-12-22 | 2022-10-31 |
| Pharmacovigilance in Gerontopsychiatric Patients Phenobarbital, Phenytoin, Carbamazepine - Dementia, Depression | Phase 3 | Terminated | Hannover Medical School | 407 | 2015-01-01 | 2018-02-28 |
| A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder Fluvoxamine maleate, Placebo - Obsessive Compulsive Disorder | Phase 3 | Completed | AbbVie | 38 | 2013-08-14 | 2017-12-04 |
| Treatment of Obsessive Compulsive Disorder in Children Serotonin reuptake inhibitors management, Cognitive behavioral therapy by a psychologist, Instructional cognitive behavioral therapy by a psychiatrist - Obsessive-Compulsive Disorder | Phase 3 | Completed | Duke University | 124 | 2003-09-01 | 2014-07-29 |
| Fluvoxamine and Sertraline in Childhood Autism - Does SSRI Therapy Improve Behaviour and/or Mood? fluvoxamine, sertraline, Placebo - Autism | Phase 3 | Completed | The Hospital for Sick Children | 108 | 1999-06-01 | 2008-04-09 |
| Treatment for Anxiety in Children Fluvoxamine - Obsessive-Compulsive Disorder, Anxiety Disorders | Phase 3 | Completed | National Institute of Mental Health (NIMH) | 1996-10-01 | 2007-06-14 |
COVID-19 (6) · Obsessive-Compulsive Disorder (3) · Post-Acute COVID-19 Syndrome (3) · Anxiety Disorders (2) · Severe Acute Respiratory Syndrome (2) · Anxiety, Separation (1) · Autistic Disorder (1) · Coronavirus Infections (1) · Delirium (1) · Dementia (1) · Depression (1) · Fatigue (1) · Fatigue Syndrome, Chronic (1) · Generalized Anxiety Disorder (1) · Phobia, Social (1)
Susanna Naggie, MD (3) · Washington University School of Medicine (3) · Cardresearch (2) · AbbVie (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Duke University (1) · Hannover Medical School (1) · National Institute of Mental Health (NIMH) (1) · The Hospital for Sick Children (1) · University of Minnesota (1)
United States (8) · Brazil (2) · Canada (2) · Germany (1) · Netherlands (1)
Adrian Hernandez, MD (3) · Susanna Naggie, MD (3) · Gilmar Reis, MD,PhD. (2) · Ben Palanca, MD (1) · Carolyn Bramante, MD (1) · Edward J Mills, FRCP (1) · Eric Lenze, MD (1) · Helge Frieling, Prof., MD (1) · John S March, MD MPH (1) · Laurence Greenhill, MD (1) · Mark Riddle, MD (1) · Sunita Vohra, MD (1) · Susumu Matsuki, BS (1)
PMID 35180412, PMID 19183470, PMID 21934055, PMID 25457929, PMID 28412602, PMID 34717820, PMID 34927127, PMID 35353979, PMID 35982649, PMID 35982669, PMID 36070710, PMID 36124697, PMID 36269852, PMID 36516104, PMID 36561174, PMID 36633838, PMID 36780676, PMID 36807465, PMID 37068273, PMID 37256990, PMID 37302406, PMID 37622035, PMID 37733308, PMID 37745371, PMID 37976072, PMID 38690892, PMID 38798524, PMID 38947738, PMID 39232602, PMID 39422912, PMID 40658388, PMID 40832427, PMID 41030935, PMID 41911553, PMID 42832803
U24TR001608 (3), R01MH055121 (1), R21AG086855 (1)